Hansa Biopharma

Capital Markets Day

Thursday 25th of June, 2026 | 9:00 AM EDT / 15:00 CEST

St. Regis Hotel, New York & Live Webcast

Featuring discussions with key opinion leaders and presentations by Hansa’s management team.

Click Here to Register & Attend
CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical’s annual report of 2010 (In Swedish) now available at corporate website

28 Apr 2011, 11:30
Regulatory information
The complete Hansa Medical Annual Report of 2010 is now available in Swedish at the corporate website www.hansamedical.com

A print version of the annual report in Swedish can be ordered at Hansa Medical AB, Investor Relations, P.O. Box 785, 220 07 Lund, Sweden, via fax +46 46-12 77 75 or via e-mail at [email protected]

Hansa Medical’s Annual General Meeting will be held May 12, 2011 at 18:00 at Scheelevägen 22 in Lund, Sweden.

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: +46 707 17 54 77
E-mail: [email protected]

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.